Almoosa Health’s $449m IPO gives UAE boards a 730-bed valuation benchmark

Almoosa Health Company raised $449 million in a 30% IPO on the Saudi Exchange, giving UAE hospital boards a listed Gulf comparator for valuation talks.

For UAE CEOs, owners and CFOs, the immediate use is practical: banks, buyers and boards can compare private hospital assets with a Saudi operator that discloses beds, doctors, revenue and profit.

What Almoosa sold

EFG Hermes, the investment banking arm of EFG Holding, said on 7 January 2025 that it completed its advisory role on the listing of Almoosa Health on Tadawul. According to Gulf Business, the company sold 13,291,074 shares at SAR 127 each, valuing the business at about SAR 5.6 billion, or roughly $1.5 billion.

The offer comprised about 9.3 million new shares and 4 million existing shares. EFG Hermes said investor demand reached 103 times the shares available. Almoosa Health began trading under the ticker ALMOOSA on 7 January 2025 and rose about 15% on debut, near SAR 139.60.

"We are proud to have played a role in the second Saudi healthcare group IPO this year and look forward to building on this momentum in 2025," said Karim Meleka, co-head of investment banking at EFG Hermes.

The operating yardstick

Almoosa Health operates 2 hospitals in Al Ahsa, with combined capacity of 730 beds. Company disclosures cited in the IPO coverage show about 1 million patients a year and 326 physicians. Almoosa Health reported SAR 979 million in revenue and SAR 98 million in net income in 2023. For the first 9 months of 2024, it reported SAR 870 million in revenue and SAR 40 million in net income.

• Almoosa Health sold 30% of issued share capital for $449 million.
• The IPO implied an equity value of about SAR 5.6 billion, or roughly $1.5 billion.
• The group disclosed 730 beds, 326 physicians and about 1 million patients a year.
• Its 2023 net margin was about 10%, based on SAR 98 million of net income and SAR 979 million of revenue.

Those numbers give UAE operators a sharper boardroom test. A Dubai hospital regulated by the Dubai Health Authority (DHA), an Abu Dhabi provider regulated by the Department of Health Abu Dhabi (DOH), or a Northern Emirates network licensed by the Ministry of Health and Prevention (MOHAP) can compare beds, physician density, revenue per bed and net margin against a listed GCC peer. Saudi payer mix and pricing differ from UAE insurance systems, so the comparison should be used as a reference point rather than a direct multiple.

Why UAE boards should watch

The UAE already has one large listed healthcare reference point. PureHealth raised AED 3.62 billion in its 2023 Abu Dhabi Securities Exchange IPO by selling 1.11 billion shares, according to Mubasher. Almoosa Health adds a different signal: a hospital-led Saudi provider with concentrated assets, disclosed bed capacity and reported patient volumes.

For UAE CFOs, the question is whether lenders start pricing private healthcare assets against listed Gulf peers with tighter margin expectations. For CEOs and owners, the number to remember is 730 beds. Almoosa Health came to market with 2 hospitals, while many UAE providers still run single-specialty clinics or small networks in 1 emirate. That scale gap could shape acquisition talks in 2025 and 2026.

Regulation remains the local constraint. Any UAE expansion plan still has to pass DHA licensing in Dubai, DOH requirements in Abu Dhabi and Al Ain, or MOHAP approvals in the Northern Emirates. Operators planning a sale or IPO should build the data room now: licences, doctor credentials, insurance receivables, occupancy, payer concentration and revenue by facility for the past 3 financial years.